Ortho Biotech reviews ESA Rxing info with FDA
Ortho Biotech Products, a Johnson & Johnson company, is in discussions with the US Food and Drug Administration regarding a safety update to the prescribing information of all erythropoiesis-stimulating agents (ESA), including Procrit (epoetin alfa), based on reports from several investigational studies evaluating ESAs. These data may have an impact on labeling in other parts of the world for Eprex (epoetin alfa), which is marketed by fellow J&J group firm Janssen-Cilag.
Although the exact language of this US label update for ESAs has not been finalized, the company expects new information will appear as a boxed warning and will apply to the oncology and nephrology indications for all marketed ESAs.
In addition, the company has been invited to participate in an upcoming Oncologic Drugs Advisory Committee (ODAC) meeting scheduled for May 10. Ortho Biotech says it supports the FDA's mission to inform healthcare professionals and the public regarding the appropriate uses of prescription therapies, and looks forward to further discussion at the upcoming ODAC event.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze